Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $58M. The Maz Rating grades it against the other companies in its sector.
Insight Molecular Diagnostics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.78, Insight Molecular Diagnostics Inc. trades at 29.6x sales. Over the last twelve months it generated about $2M of revenue and a net loss of $42M. It runs a gross margin of 23.7%, an operating margin of -1795.8% and a net margin of -2137.3%. It shows return on equity of 192.1%, return on invested capital of -255.4% and a free cash flow yield of -56.8%. On the balance sheet: a debt-to-equity ratio of -0.09 and a current ratio of 1.46. Over the past 52 weeks the share price ranged from $1.63 to $7.51, with a beta of 1.86.
Insight Molecular Diagnostics Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 7 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Insight Molecular Diagnostics Inc. functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, Insight Molecular Diagnostics provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. Insight Molecular Diagnostics was founded in 2009 and maintains its principal office in Irvine, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Insight Molecular Diagnostics Inc. (IMDX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.72% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.72% / 33% · Receivables / Mkt Cap (36m) 0.41% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.72% / 33.33% · Receivables / Mkt Cap (24m) 0.41% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 1.11% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 58.4% / 33.33% · Receivables / Avg Assets (4Q) 1.70% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 50.7% / 33.33% · (Cash+Recv) / Total Assets 53.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Insight Molecular Diagnostics Inc. (IMDX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Insight Molecular Diagnostics Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Insight Molecular Diagnostics Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.